Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)
Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION)
Sponsor: Merck KGaA, Darmstadt, Germany
A PHASE3 clinical study on Clinically Isolated Syndrome and Multiple Sclerosis, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Barcelona, Spain , Beirut, Lebanon , Belgrade, Serbia , Bialystok, Poland , Bilbao, Spain , Bruges, Belgium , Bucharest, Romania , Graz, Austria , Hanover, Germany and 47 more locations